Case Study:
Using Real World Data To Uncover Patient Journeys
Using Real World Data To Uncover Patient Journeys
The classic approach to understanding a patient treatment journey is through market research. This is a decent approach but may not show the full picture if the sample is too small. This client wanted to use real world big data to pull out the patient treatment journey.
The Client
The condition involved some changing dynamics with the introduction of some new drugs that changed the treatment approach. The client wanted to understand the impact this was having on the traditional patient journey and how the physicians were changing their treatment approach based on the new entrants.
The Solution
For this project we used multiple claims data sets that were longitudinal. Time series databases were also employed to speed up the process. In addition, Electronic Healthcare Record and Electronic Medical Record data were also available.
The Outcome
The various pathways of the patient journey were uncovered (as well as the critical tests done at each stage and which test results led to which next action and which drug class and which drug brand. Then we were able to add a consulting layer on top and identify specific leverage points at which the patient journey could be positively impacted towards our client drug (where appropriate for the patient).
To achieve these kinds of results, contact Eularis today.
Latest News
Read our latest blogs here.

Are LLMs Already On Their Way to Being Obsolete?
The AI world is racing forward with near-religious confidence in large language models, yet one of the field’s most influential pioneers is already drafting their

CRO 2.0: Transforming Tomorrow’s Clinical Research Process with Artificial Intelligence
The clinical trial ecosystem – a $90 billion engine driving medical innovation is struggling under the burden of its own complexity. Despite significant advancements in

The Hidden Cost of Having No AI Strategy (Spoiler: It’s Not What You Think)
In the past few years, almost 70% of biopharma companies have initiated AI initiatives. Yet, fewer than 20% report a cohesive AI strategy at the